Describes a drop in shares in Britain's biotechnology sector because Celltech halted trials with CDP840, a potential asthma drug. Celltech's own shares dropping 25 percent immediately following the news; Reason why the company and its partner, Merck Sharp and Dohme, decided to halt the trial.